WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.084
Volume 11, Issue 5, 1985-1997. Review Article ISSN 2277– 7105

ICH GUIDELINES FOR IMPURITY PROFILE

Gottipati Meghana*, Sampathi Mahi Varshini, Mohamad Ali Ahamad, M. V. Nagabhushanam, Y. Ratna Sindhu, Brahmaiah Bonthagarala, G. Ramakrishna, Santosh Kumar CH.

Department of Pharmaceutical Regulatory Affairs, Hindu College of Pharmacy, Amaravathi Road, Guntur, Andhra Pradesh, India-522002.

Article Received on
20 March 2022,

Revised on 10 April 2022,
Accepted on 30 April 2022

DOI: 10.20959/wjpr20225-23842

***Corresponding Author**
Gottipati Meghana
Department of Pharmaceutical Regulatory Affairs, Hindu College of Pharmacy, Amaravathi Road, Guntur, Andhra Pradesh, India-522002.

ABSTRACT

Drug impurities are the natural and inorganic undesirable synthetic compounds which are found in dynamic drug fixing after combination or create during plan advancement. These impurities seriously influence the wellbeing and viability of created drug item. Pollutant profiling recognizes and measures the degrees of natural and inorganic impurities and in this manner helps in better observing of value, solidness and security of drug items. Administrative bodies overall are not kidding towards presence of impurities and pollution profiling has in this way turned into a significant stage in filling drug dossiers. The ICH guidelines on pollutant have plainly characterized the degrees of harmful impurities and have become benchmark in laying out impurities in drug items. The current article sums up the idea of debasement profiling and furthermore presents a contextual investigation on pollution profiling of methamphetamine hydrochloride to show its importance. Further a contextual investigation is introduced on evaluation of dynamic drug fixing and impurities in sildenafil citrate bought through web and its relative results.

KEYWORDS: Impurities, Impurity profiling, ICH guidelines, USFDA, Pharmaceutical product.

1. INTRODUCTION

In the current period, there has been a steadily expanding interest in debasement profiling in the pharmaceutical business. This is because of the way that even follow level of impurities can unfavorably influence both the wellbeing and adequacy of the pharmaceutical medication

item. A portion of the impurities shaped can likewise be mutagenic or teratogenic. In this manner, there is a requirement for controlling the degree of impurities present inside limits in both medication substances and medication products. ICH has distributed guidelines on the impurities in new medication substances, new medication products, lingering solvents and natural impurities.[1]

Impurity

ICH characterizes impurities concerning pharmaceutical products; the control of impurities is a basic issue for pharmaceutical Industry. Impurities are any natural material other than the medication substances and excipients might be depicted as impurities. Impurities in pharmaceuticals are the undesirable synthetic substances that stay with the dynamic pharmaceutical fixings (APIs), or create during plan or after maturing of the two API and figured out APIs to meds. The presence of these undesirable synthetics even in limited quantities might impact the viability and wellbeing of the pharmaceutical products.[2]

Impurity profiling

There is no exact definition for impurity profile. It gives a bookkeeping of impurities present in it. Pollution profile is a portrayal of the recognized and unidentified impurities existing in an ordinary clump of API (Active Pharmaceutical Ingredient) created by an exact controlled creation process. It incorporates the character or any subjective scientific assurance (for example maintenance time), the scope of every pollution distinguished and sort of each recognized contamination. Contamination profile of a substance being scrutinized gives most extreme potential sorts of impurities present in it. It additionally appraises the genuine measure of various types of impurities present in it. For every API there should be a pollutant profile portraying the distinguished and unidentified impurities present in a regular clump. The pollution profile is regularly reliant upon the cycle or beginning of the API.[3] The general plan for pollution profiling is displayed in Fig. 1.[4]

Administrative specialists are additionally underlining on not just the immaculateness profile yet on debasement profiling (ID, seclusion and portrayal of pollutant) for the authorizing reason and administrative related issues for specific medication substance and medication item. Various pharmacopeias like British Pharmacopeia (BP), European Pharmacopeia (EP), Indian Pharmacopeia (IP), Japanese Pharmacopeia (JP) and United States Pharmacopeia (USP) are likewise modifying their monographs for the medication substances and medication products consistently by presenting the cutoff points for the various sorts of

impurities.[5] The Classification of impurities according to various phrasings is displayed in Fig. 2.[6,7]



Figure 1: General scheme for Impurity profiling.



Figure 2: Classification of Impurities As per different Terminologies.

Sources of Impurities

Compound explored in drug disclosure prompts a critical scientific test for the portrayal, quantization, and identification of the mixtures.[8] Fig. 2 sums up all classes of impurities. Following are the different wellsprings of impurities in pharmaceutical products:

- Organic impurities (process-drug related /interaction and medication related): They can be distinguished or unidentified, unpredictable or non-unstable, and it's included: Starting materials, By-products, Intermediates, Degradation products, Reagents, ligands and impetuses.
- Inorganic impurities: They are typically distinguished and it's included: Reagents, ligands and impetuses, Heavy metals or other remaining metals, Inorganic salts other materials (e.g., channel helps, charcoal)
- Miscellaneous Impurity: They are inorganic or natural fluids utilized as vehicles for the planning of arrangements or suspensions in the combination of another medication substance. They are ordinarily polymorphic structures and enantiomeric pollution.[9]

2. GLOBAL REGULATORY GUIDELINES

The significant global guidelines on impurity and impurity profiling are as follows:

ICH (International Council on Harmonization): The International Council on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) is a venture that unites the administrative specialists of Europe, Japan and the United States and specialists from the pharmaceutical business in the three locales to talk about logical and specialized parts of pharmaceutical item enrollment.[10]

The Guidelines of impurity profiling in ICH are mentioned below.

A. Impurities in New Drug Substances Q3A (R2)

B. Impurities in New Drug Products Q3B (R2)

C. Impurities: Guideline for Residual Solvents Q3C (R5)

D. Guideline for Elemental Impurities Q3D

A) Impurities in New Drug Substances Q3A (R2)

The principle objective of the Q3A (R2) rule is to give guidance to enlistment applications on the substance and capability of impurities in new medication substances delivered by compound blend. Natural/biotechnological, peptide, oligonucleotide, radiopharmaceutical, maturation item and semi-manufactured products got there from, home grown products, and rough products of creature or plant beginning are not covered by this rule.[11]

B) Impurities in New Drug Products Q3B (R2)

The fundamental goal of the Q3B (R2) rule is to give direction to enrollment applications on the substance and capability of impurities in new medication products delivered from synthetically incorporated new medication substances not recently enlisted in an area or part state. Just those impurities in new medication products named excipient and/or quick compartment conclusion framework are tended to in this rule.[12]

C) Impurities: Guideline for Residual Solvents Q3C (R5)

The principle objective of the Q3B (R2) rule is to suggest OK sums for lingering solvents in pharmaceuticals for the wellbeing of the patient. The motivation behind giving satisfactory degrees of leftover dissolvable is to suggest utilization of less harmful solvents and to portray levels of remaining solvents which are toxicologically adequate in pharmaceutical products.[13]

D) Guideline for Elemental Impurities Q3D

The primary target of the Q3D rule applies to new completed drug products and new medication products containing existing medication substances. The medication products containing purged proteins and polypeptides. This rule doesn't matter to home grown products, radiopharmaceuticals, immunizations, cell metabolites, DNA products, allergenic concentrates, cells, entire blood, cell blood parts or blood subordinates including plasma and plasma subsidiaries.[14]

United States Food and Drug Administration (USFDA)

The U.S. Food and Drug Administration (FDA or USFDA) is an office of the United States Department of Health and Human Services and is answerable for controlling and regulating the security of food varieties, dietary enhancements, drugs, immunizations, organic clinical products, blood products, clinical gadgets, radiation-emanating gadgets, veterinary products, and beauty care products.[15]

The guidelines of impurity profiling in USFDA are mention below.

- Impurities in New Drug Substances Q3A[16]
- Impurities in New Drug Products Q3B (R2)[17]
- ANDAs: Impurities in Drug Substances
- ANDAs: Impurities in Drug Products

ANDAs: Impurities in Drug Substances

The fundamental goal of the ANDA'S rule is to give overhauled suggestions on what science, assembling, and controls (CMC) data to incorporate with respect to the revealing, distinguishing proof, and capability of impurities in drug substances created by synthetic combination while submitting:

- Original abbreviated new drug applications (ANDAs)
- Drug master files (DMFs) including type II DMFs
- ANDA supplements for changes in the synthesis or processing of a drug substance.[18]

ANDAs: Impurities in Drug Products

The principal objective of the ANDA'S rule is to give suggestions on what science, assembling, and controls (CMC) data supporters ought to incorporate in regards to the announcing, distinguishing proof, and capability of impurities that are named debasement products in drug products while submitting:

- Original abbreviated new drug applications (ANDAs)
- ANDA supplements for changes that may affect the quantitative or qualitative degradation product profile.[19]

Control of impurities in active pharmaceutical ingredients (API)

During crystallization, the synthetic substances from the debasement of medication are entangled. So, API producer should play it safe to deliver better gems to forestall entanglement. Washing ought to be legitimate to eliminate undesirable synthetics including remaining solvents. Photograph delicate pharmaceuticals must be stuffed in legitimate manner to forestall openness of light. Creation strategy should be founded on strength study. In the event of diclofenac sodium infusions, the aseptic filtration process was utilized rather than the autoclave technique to yield quality item. Over all pharmacopeias should be more cutoff explicit, exact and administrative specialists like ICH and FDA ought to be severe in regards to this.[20]

Applications and Significance of impurity profiling

Contamination profiling have observed application in checking quality and strength of pharmaceutical mixtures, whether created artificially, extricated from normal products or delivered by recombinant strategies. Contamination profiling have helped in recognizing and resulting evacuation of impurities in a few medications item nearby sedatives and steroids.[21,22] Table 1 shows impurities and technique for examination of a few medications. Following are the significant meaning of pollutant profiling:

- ❖ Helps in recognizable proof and measurement of mixtures.
- ❖ It guarantees that the impurities give are inside the cutoff points as explicit under ICH guidelines.
- ❖ Improvement of current insightful techniques, the beginning of impurities can be resolved whether it is blend related pollutant (Organic/Inorganic/Residual solvents), or plan related debasement (Dosage structure/Method/Environmental related contamination), or corruption related contamination, or different impurities (Enantiomeric/Polymorphic/Genotoxic pollution).
- ❖ Helps in charge framework for impurities including handling or assembling conditions, bundling and detailing.[23]

- If there should arise an occurrence of union related impurities: an elective course for the combination of the API can be created or the reagent (lingering dissolvable) not entirely settled.
- If there should arise an occurrence of definition related impurities: An excipient which influences the steadiness of b API is hence not joined in the plan of the API or natural circumstances can be controlled to keep away from debasement of the API.
- If there should arise an occurrence of corruption related impurities: the potential debasement products not entirely settled through pressure testing and genuine corruption products through soundness review.

Table 1: Current Marketed Formulation Which Contain Impurity.

DRUG	IMPURITY	METHOD
Amphotericin B	Tetraenes	UV spectroscopy
Atropine sulphate	Apo atropine	UV spectroscopy
Cloxacillin	N, N dimethyl aniline	GC
Dextrose	5 hydroxyl methyl furfurals	UV spectroscopy
Doxorubicin HCL	Acetone and ethanol	GC
Ethambutol HCL	2 amino butanol	TLC
Fluorescence sodium	Dimethyl formamide	GC
Framycetin sulphate	Neamine	TLC
Mercaptopurine	Hypoxanthine	UV spectroscopy
Deferesirox	Deferesirox A and B	HPLC-UV
Dup941	PC, SL, LS	LC-UV diode array
Trinitrotoluene	2, 4-dinitrotoluene	GC-MS
Lumefantrine	Desbenzylketo derivative	HPLC-DAD/UV-ESI/MS
Pholcodine	Pholcodine A, B, C	LC-ESI-MS
Mycophenolate mofetil	Mycophenolic acid	LC/DAD/LC/MS/MS

- In case of other impurities:

- Polymorphic debasement: The polymorphic type of the API present in the definition can be qualified. The strength of the polymorphic structure in the detailing still up in the air.[24]
- Enantiomeric contamination: The presence of the right enantiomer (answerable for helpful movement of the API) in the plan can be confirmed.[25,26]
- Genotoxic pollutant: The wellspring of genotoxic contamination not entirely set in stone (beginning material/reagents/impetus) and accordingly be forestalled. The genotoxic pollution can be ordered and its gamble not entirely settled.[27]

Case Study on Identification of Impurities

Because of the rising number of medication cases, as well as the extending globalization of illegal medications, regulation implementation organizations worldwide have embraced the system of profiling of medication impurities. Itemized pollution data has been accounted for on the methamphetamine drugs seized in nations, for example, the European Commission, Japan, Thailand, Korea, the Philippines and Australia, where methamphetamine misuse is one of the most genuine medication issues. The data acquired can be utilized to lay out drug dealing examples and dissemination organizations, and to distinguish techniques utilized in the assembling of illegal medications.

Methamphetamine hydrochloride is at present one of the most generally involved unlawful medications in the China. Be that as it may, in the open writings there has been little data accessible on pollution attributes or profiling of methamphetamine drug seizures in China. A sum of 48 methamphetamine hydrochloride tests from eight seizures were investigated utilizing gas chromatography-mass spectrometry (GC-MS) and a fire ionization finder (GC-FID).

Eight captures of Methamphetamine hydrochloride from BPSB caught somewhere in the range of 2006 and 2007 were examined. Ordinarily the seizures were gems and had a virtue of over 95%. Every one of seizures weighed over 400g and had a place with a pack.

The substance of each chosen pack (seizure) was separated into six examples. Subsequently, a sum of 48 examples were acquired. 10g were weighed out from each example and squashed. Fifty milligrams were taken for examination. Each example was breaking down multiple times to decide the inconstancy inside every seizure and whether the examples from a similar pack (seizure) have a place with a similar cluster.

The current strategy offers unrivaled division of impurities in methamphetamine hydrochloride precious stones utilizing chromatographic methods. The 17 pinnacles chose were trademark and symptomatic for the arrangement and examination of chromatograms. The Euclidean distance of 17 relative pinnacle regions after logarithmic change was successful for the assessment of comparability and additionally disparity of pollutant profiles.

The primer work shows that it is exceptionally valuable for getting insight from methamphetamine pollutant profiling. Data about the impurities in methamphetamine permitted recognizable proof of the medication manufactured courses.

In the medications produced through the ephedrine course where the marker compounds, the aziridines or naphthalene's, were available unmistakably.[28]

Case Study on Qualification of active pharmaceutical ingredient and impurities in sildenafil citrate obtained from the Internet[30-33]

Purchasers can get doctor prescribed drugs by means of the Internet with practically no trouble and expert oversight. The openness of physician endorsed drugs created outside of the United States, most eminently sildenafil citrate (trend-setter item, Viagra®), has been made a lot more straightforward by the Internet. Clinicians and policymakers are more worry to item quality and patient security. The US Food and Drug Administration (FDA) has given alerts to potential purchasers that the security of medications bought from the Internet can't be ensured and may introduce a wellbeing hazard to customers from inadequate products.

A review was led to decide if nonexclusive sildenafil citrate tablets from global business sectors got by means of the Internet are identical to the US trailblazer item with respect to significant parts of pharmaceutical quality: power, exactness of naming, and presence and level of impurities. As in the event that an aggregate of 15 sildenafil citrate tablets were removed for pharmaceutical investigation from which 14 conventional examples from global Internet drug store sites and one was trend-setter item. As per US Pharmacopeial guidelines, tablet tests were tried involving superior execution fluid chromatography for power of dynamic pharmaceutical fixing (API) and levels of (impurities A, B, C, and D). Pollutant levels were contrasted and International Conference on Harmonization (ICH) limits. As result of among 15 examples, 4 examples had higher debasement B levels than the ICH capability edge, 8 examples had higher contamination C levels than the ICH capability edge, and 4 examples had over 1% pollutant amount of most extreme day to day portion (MDD). For API, 6 of the examples neglected to fall inside the 5% test limit.

Results of study uncovered that in those assembling principles for sildenafil citrate conventional medication products contrasted and the US pioneer item are not identical with respect to intensity and levels of impurities. They have suggestions for wellbeing and

viability that ought to be addressed by clinicians to shield buyers who decide to buy sildenafil citrate and unfamiliar fabricated drugs, through the Internet.[29]

3. CONCLUSION

Impurity profiling has acquired monstrous importance in pharmaceutical item improvement. New strategies are being investigated to distinguish and lay out the degrees of impurities in drug products which at last assistance in its quality and security checking. The ICH guidelines give extensive guidelines on impurities and carrying out these guidelines assist pharmaceutical organizations with delivering drug products which are liberated from impurities or in which the harmful impurities are in wanted levels.

4. REFERENCES

1. D' Souza j, Gangrade D and Khor M. Impurity profiling: A necessity in the pharmaceutical industry. International Journal of Innovative Pharmaceutical Science and Research, 2014; 2(7): 1587-605.
2. Patil P and Vaidya I. Overview on Impurity Profiling: International Journal for Pharmaceutical Research Scholars, 2014; 2(2): 54-5.
3. Ingale, SJ, Paliwal RT, and Singhai AK. Advance approaches for the impurity profiling of pharmaceutical. International Journal of Pharmacy & Life Science, 2011; 2(3): 955-62.
4. Ingale S, Sahu C and Paliwal RT. Advance approaches for the impurity profiling of pharmaceutical drugs: A review. International Journal of Pharmacy & Life Science, 2014; 2: 923-63.
5. Pilaniya K, Pilaniya U, Jain P and Singh N. Recent Trends in the Impurity Profile of Pharmaceuticals. Journal of Advanced Pharmaceutical Technology and Research, 2014; 1(3): 302-10.
6. ICH Harmonized Tripartite Guideline. Impurities in New Drug Substances Q3A (R2). ICH Steering Committee, Step 4 of ICH process; 25th Oct. 2013.
7. Ahuja S. Assuring quality of drugs by monitoring impurities. Advanced Drug Delivery Reviews, 2012; 5(7): 3-11.
8. Misra B, Thakur A and Mahata PP. Pharmaceutical Impurities: A Review. International Journal of Pharmaceutical Chemistry, 2015; 5(7): 232-39.
9. Sources of Impurities. Available from: http://www. ich.org/ fileadmin/ Public_Web_Site/ICH_Products/Guidelines/Quality/Q3A_R2/Step4/Q3A_R2__Guideline.pdf; 10th Dec. 2015.

10. Introduction to ICH. Available from: https://en. wikipedia.org/wiki/ International_ Conference on_ Harmonisationof_Technical_Requirements_for_Registrati on_of_Pharmaceuticals_for_Human_Use; 26th Apr. 2016.
11. Introduction to Guideline of Impurities in New Drug Substances Q3A (R2). Available from: http://www.ich. org/fileadmin/Public_Web_Site/ICH Products/Guidelines/ Quality/Q3 A_R2/Step4/Q3A_R2__Guideline.pdf; 10th Dec. 2015.
12. Introduction to Guideline of Impurities in New Drug Products Q3B (R2). Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICHProducts/Guidelines/Qualiy/Q3B_R2 /Step4/Q3B_R2__Guideline.pdf; 14th Dec. 2015.
13. Introduction to Impurities: Guideline for Residual Solvents Q3C (R5). Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH Products/Guidelines/Quality/Q3C/ Step4/Q3C_R5_Step4.pdf; accessed on 19th Dec. 2016.
14. Introduction to Guideline for Elemental Impurities Q3D. Available from: http://www.ich.org/fileadmin/Public_ Website/ICHProducts/Guidelines/Quality/Q3D/Q3 D_St ep_4.pdf; 26th Dec. 2015.
15. Introduction of USFDA. Available from: http://www. authorstream.com Presentationdevanshi 2 soni - 927841- usfda; accessed on 28th Apr. 2017.
16. Introduction to Guideline of Impurities in New Drug Substances Q3A. Available from: http://www.fda.gov/ downloads/drugs/guidancecomplianceregulatoryinformatio n/guidance/ucm073385.pdf; accessed on 28th Dec. 2016.
17. Introduction to Guideline of Impurities in New Drug Products Q3B (R2). Available from: http://www.fda.gov/ downloads/drugs/guidancecomplianceregulatoryinformatio n/guidance/ucm073389.pdf; accessed on 29th Dec. 2016.
18. Introduction to Guideline of ANDAs: Impurities in Drug Substances. Available from: http://www.fda.gov/ downloads/drugs/guidance compliance regulatory information/guidance/ucm072861.pdf; accessed on 29th Dec. 2016.
19. Introduction to Guideline of ANDAs: Impurities in Drug Products. Available from: http://www.fda.gov/ downloads/ Drugs/.../Guidance's/UCM172002.pdf; accessed on 30th Dec. 2016.
20. ICH Harmonized Tripartite Guideline Validation of Analytical Procedures: text and methodology Q2 (R1), 2014; 5: 3-11.
21. Venkatesan P and Valliappan K. Impurity Profiling: Theory and Practice. Journal of Pharmaceutical Science and Research, 2013; 5: 3-11.

22. Roy J, Islam M, Khan AH, Das SC, Akhteruzzaman M, Deb AK and Alam AH M. Diclofenac sodium injection sterilized by autoclave and the occurrence of cyclic reaction producing a small amount of impurity. Journal of Pharmaceutical Science, 2013; 2(9): 541-44.
23. Bari S, Kadam B, Jaiswal Y, and Shirkhedkar A. Impurity Profile: Significance in Active Pharmaceutical Ingredient. Eurasian Journal of Analytical Chemistry, 2013; 2(1): 32-53.
24. Wadekar R, Bhalme M, Rao S, Reddy K and Kumar L. Evaluating Impurities in Drugs. Pharmaceuticals Technology, 2014; 36(3): 58-72.
25. Tegeli V, Gajeli G, Chougule G, Throat Y and Kumbhar S. Significance of impurity profiling: A review. International Journal of Drug Formulation and Research, 2014; 2(4): 174-95.
26. Parimoo P. A Text Book of Pharmaceutical Analysis. CBS Publishers and distributors. New Delhi, 2014; 14.
27. Pierson D, Olsen B, Robbins D, De Vries K and Varie D. Approaches to Assessment, Testing Decisions, and Analytical Determination of Genotoxic Impurities in Drug substances. Organic Process Research and Development, 2012; 13(2): 285-91.
28. Zhang JX, Zhang DM and Han XG. Identification of impurities and statistical classification of Methamphetamine hydrochloride drugs seized in the China. Forensic Science International, 2012; 182(13): 13–19.
29. Veronin MA, Nutan MT and Reddy Dodla UK. Case study on Quantification of active pharmaceutical ingredient and impurities in sildenafil citrate obtained from the Internet. Therapeutic Advances in Drug Safety, 2014; 182(5): 180–89.
30. Brahmaiah Bonthagarala, Regulatory Requirements for Registration of Generic Drugs in "BRICS" Countries, International Journal of Pharmaceutical Science and Health Care, ISSN 2249 – 5738, November-December 2016; 6(6): 20-39.
31. Brahmaiah Bonthagarala*l*, Current Regulatory Requirements for Registration of Medicines, Compilation and Submission of Dossier in Australian Therapeutic Goods Administration, International Journal of Advanced Scientific and Technical Research, ISSN 2249-9954, November-December 2016; 6(6): 144-157.
32. Brahmaiah Bonthagarala, Comparison of Regulatory Requirements for Generic Drugs Dossier Submission in United States and Canada, International Journal of Pharmaceutical Science and Health Care, ISSN 2249 – 5738, November-December 2016; 6(6): 1-19.
33. Brahmaiah Bonthagarala, Nanomedicine Clinical Use, Regulatory And Toxicology Issues In Europe, Journal of Drug Delivery and Therapeutics, 2019; 9(4-s): 846-848.